// App-Quantinova.ai

170 : Secukinumab provides sustained improvement in function, quality of life and fatigue over two years in patients who achieved low disease activity related to psoriatic arthritis disease activity score

Researchers

Presenter

  • Laura C Coates

Principal Investigators

  • Tore K Kvien

  • Peter Nash

  • Laure Gossec

  • Vibeke Strand

  • Luminita Pricop

  • Lawrence Rasouliyan

  • Kevin Ding

  • Steffen Jugl

  • Corine Gaillez

Medical Centers

  • Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

  • Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

  • Medicine, University of Queensland, Queensland, AUSTRALIA

  • Rheumatology, UPMC University Paris 06 and Pitie-Salpétriere Hospital, Paris, FRANCE

  • Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, CA

  • Oncology Clinical Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ

  • Biostatistics, RTI Health Solutions, Barcelona, Spain,

  • Immunology, Dermatology and Rheumatology/Autoimmunity, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

  • Immunology & Dermatology Franchise, Novartis Pharma AG, Basel, SWITZERLAND

Locations

  • United Kingdom

  • Norway

  • Australia

  • France

  • United States

  • Spain

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

Biomarkers

  • C reactive protein

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved